 Connection
Carolina Schinke to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Carolina Schinke has written about Xenograft Model Antitumor Assays.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.165 |
|
|
|
-
Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreyro L, Barreryo L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will B, Wei S, Steidl U, Verma A. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood. 2015 May 14; 125(20):3144-52.
Score: 0.108
-
Sabol HM, Paxton BC, Anloague A, Kaur J, Nester MR, Khan S, Smith J, Croucher PI, McDonald MM, Montgomery CO, Stambough JB, Barnes CL, Ambrogini E, Ebetino FH, Schinke C, Ashby C, Delgado-Calle J. Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells. J Exp Clin Cancer Res. 2026 Jan 05; 45(1):31.
Score: 0.057
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|